Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>G Sachs Drops WUXI XDC (02268.HK) TP to $85.9 as 2026 Guidance in Line
Recommend 0 Positive 0 Negative 0 |
||||
|
||||
|
WUXI XDC (02268.HK) reported 2H25 results that were largely in line with its earlier alert, with revenue increasing by 35.9% YoY, and net profit ring by 26.4% to RMB735 million, Goldman Sachs published a research report saying. The management's 2026 guidance was in line with expectations. At a constant exchange rate, based on a comparable basis (including BioDlink CDMO business for both years), 2026 revenue will grow by approx. 35%. On a pro forma basis (assuming the BioDlink acquisition is completed by the end of March, compared to WUXI XDC's standalone business in 2025), the growth is expected to be 40%. Goldman Sachs raised its 2026-2028 adjusted net profit forecasts for WUXI XDC by +1.8%/ +1.4%/ -0.1%, reflecting the commencement of production at the Singapore plant, although partially offset by depreciation and amortization costs mostly recognized in 2027. Therefore, the broker kept rating at Buy, and dropped its target price from $87.1 to $85.9. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
